[Adverse effects of inotropic drugs in hypertrophic cardiomyopathy].
Pérez-Cimarra
C
C
Font
C
C
Gredilla
E
E
Gilsanz
F
F
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D001803:Blood Transfusion; D002316:Cardiotonic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003102:Colloids / Q000627:therapeutic use; D000075202:Contraindications; D004280:Dobutamine / Q000009:adverse effects* / Q000627:therapeutic use; D004298:Dopamine / Q000009:adverse effects* / Q000627:therapeutic use; D017558:Elective Surgical Procedures; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications; D017379:Hypertrophy, Left Ventricular / Q000150:complications* / Q000175:diagnosis / Q000503:physiopathology; D007022:Hypotension / Q000150:complications* / Q000188:drug therapy; D007045:Hysterectomy, Vaginal; D007431:Intraoperative Complications / Q000188:drug therapy*; D009638:Norepinephrine / Q000009:adverse effects* / Q000627:therapeutic use; D012769:Shock / Q000150:complications* / Q000188:drug therapy
D000319:Adrenergic beta-Antagonists; D002316:Cardiotonic Agents; D003102:Colloids; D004280:Dobutamine; D004298:Dopamine; D009638:Norepinephrine